Free Trial
→ This Is The Moment You Betray Trump (Or Prove Them Wrong) (From Colonial Metals) (Ad)

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Written by MarketBeat Staff
May 18, 2023

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • MarketBeat previews the top five stocks to own by June 1st.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
3.8673 of 5 stars		$14.39-0.3%N/A-5.21Buy$33.79
Ultragenyx Pharmaceutical (RARE)
4.2211 of 5 stars		$35.16-2.3%N/A-5.55Moderate Buy$90.93
Sarepta Therapeutics (SRPT)
4.7237 of 5 stars		$36.27-0.7%N/A29.02Moderate Buy$131.22
Pfizer (PFE)
4.9993 of 5 stars		$22.28-3.0%7.72%15.80Moderate Buy$29.17
Exelixis (EXEL)
4.183 of 5 stars		$36.17-0.9%N/A20.44Hold$37.59
Moderna (MRNA)
4.419 of 5 stars		$24.25-0.5%N/A-2.61Hold$53.95
United Therapeutics (UTHR)
4.9785 of 5 stars		$301.42-2.1%N/A13.24Moderate Buy$392.00
Biogen (BIIB)
4.7363 of 5 stars		$118.20-0.2%N/A10.56Hold$191.30
Sanofi (SNY)
4.3408 of 5 stars		$49.98-4.1%3.20%20.07Buy$63.33
Eli Lilly and Company (LLY)
4.9918 of 5 stars		$736.21-2.0%0.81%62.87Moderate Buy$1,002.80
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

5 Blowout Earnings Winners That Could Soar Even Higher
5 Stocks You’ve Never Heard Of That I’m Buying Nonstop in 2025
3 Sectors With Massive Momentum You Can’t Afford to Miss

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines